English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/188027
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

A role for CXCR4 in peritoneal and hematogenous ovarian cancer dissemination

AuthorsFigueras, Agnès; Alsina-Sanchís, Elisenda; Lahiguera, Álvaro; Abreu, Manuel; Muinelo-Romay, Laura; Moreno-Bueno, Gema ; Casanovas, Oriol; Graupera, Mariona; Matías-Guiu, Xavier; Vidal, August; Villanueva, Alberto; Viñals, Francesc
Issue Date2018
PublisherAmerican Association for Cancer Research
CitationMolecular Cancer Therapeutics 17(2): 532-543 (2017)
AbstractEpithelial ovarian cancer is characterized by a low recovery rate because the disease is typically diagnosed at an advanced stage, by which time most patients (80%) already exhibit disseminated neoplasia. The cytokine receptor CXCR4 has been implicated in the development of metastasis in various tumor types. Using a patient-derived tissue macroarray and mRNA expression analysis, we observed high CXCR4 levels in high-grade serous epithelial ovarian carcinomas, the most metastatic tumor, compared with those in endometrioid carcinomas. CXCR4 inhibition by treatment with the CXCR4 antagonist AMD3100 or by expression of shRNA anti-CXCR4 similarly inhibited angiogenesis in several models of ovarian carcinomas orthotopically grown in nude mice, but the effect on tumor growth was correlated with the levels of CXCR4 expression. Moreover, CXCR4 inhibition completely blocked dissemination and metastasis. This effect was associated with reduced levels of active Src, active ERKs, the inhibition of EMT transition, and block of hematogenous ovarian cancer dissemination decreasing circulating human tumoral cells (CTC). In tumors, CXCR4-expressing cells also had more mesenchymal characteristics. In conclusion, our results indicate that CXCR4 expression confers a proinvasive phenotype to ovarian carcinoma cells. Thus, anti-CXCR4 therapy is a possible agent for a complementary treatment of advanced disseminated epithelial high-grade serous ovarian cancer patients.
Publisher version (URL)https://doi.org/10.1158/1535-7163.MCT-17-0643
URIhttp://hdl.handle.net/10261/188027
DOIhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0643
ISSN1535-7163
E-ISSN1538-8514
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.